NEW YORK, March 13, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Fenix Parts, Inc. (NASDAQ:FENX) securities between May 14, 2015 and October 12, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/fenix-parts-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fenix had an inadequate inventory valuation methodology; (2) Fenix had an inadequate methodology to calculate goodwill impairment; (3) Fenix was engaging and/or had engaged in conduct that would result in an SEC investigation; and (4) as a result, Defendants’ statements about Fenix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Fenix Parts you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/fenix-parts-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 



